Navigation Links
Novel analyses improve identification of cancer-associated genes from microarray data
Date:5/2/2014

Dartmouth Institute for Quantitative Biomedical Sciences (iQBS) researchers developed a new gene expression analysis approach for identifying cancer genes. The paper entitled, "How to get the most from microarray data: advice from reverse genomics," was published online March 21, 2014 in BMC Genomics. The study results challenge the current paradigm of microarray data analysis and suggest that the new method may improve identification of cancer-associated genes.

Typical microarray-based gene expression analyses compare gene expression in adjacent normal and cancerous tissues. In these analyses, genes with strong statistical differences in expression are identified. However, many genes are aberrantly expressed in tumors as a byproduct of tumorigenesis. These "passenger" genes are differentially expressed between normal and tumor tissues, but they are not "drivers" of tumorigenesis. Therefore, better analytical approaches that enrich the list of candidate genes with authentic cancer-associated "driver" genes are needed.

Lead authors of the study, Ivan P. Gorlov, Ph.D., Associate Professor of Community and Family Medicine and Christopher Amos, Ph.D., Professor of Community and Family Medicine and Director of the Center for Genomic Medicine described a new method to analyze microarray data. The research team demonstrated that ranking genes based on inter-tumor variation in gene expression outperforms traditional analytical approaches. The results were consistent across 4 major cancer types: breast, colorectal, lung, and prostate cancer.

The team used text-mining to identify genes known to be associated with breast, colorectal, lung, and prostate cancers. Then, they estimated enrichment factors by determining how frequently those known cancer-associated genes occurred among the top gene candidates identified by different analysis methods. The enrichment factor described how frequently cancer associated genes were identified compared to the frequency of identification that one could expect by pure chance. Across all four cancer types, the new method of selecting candidate genes based on inter-tumor variation in gene expression outperformed the other methods, including the standard method of comparing mean expression in adjacent normal and tumor tissues. Dr. Gorlov and colleagues also used this approach to identify novel cancer-associated genes.

The authors cite tumor heterogeneity as the most likely reason for the success of their variance-based approach. The method is based on the knowledge that different tumors can be driven by different subsets of cancer genes. By identifying genes with high variation in expression between tumors, the method preferentially identifies genes specifically associated with cancer. This same feature, tumor heterogeneity, may reduce the ability to identify critical gene expression changes when comparing mean gene expression in adjacent tumor and normal tissues, as tumors of the same type may have different sets of genes differentially expressed.

The results of the study challenge the model that comparing mean gene expression in adjacent normal and cancer tissues is the best approach to identifying cancer-associated genes. Indeed, the team identified high variation in adjacent "normal" tissue samples, which are typically used as control samples for comparison in analyses based on mean gene expression. The study suggests that methods based on variance may help get the most from existing and future global gene expression studies.


'/>"/>

Contact: Derik Hertel
derik.hertel@dartmouth.edu
603-650-1211
The Geisel School of Medicine at Dartmouth
Source:Eurekalert

Related medicine news :

1. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
2. Rutgers team discovers novel approach to stimulate immune cells
3. Novel drug candidates offer new route to controlling inflammation
4. Researchers present new findings for novel pancreatic cancer vaccine
5. Novel biomarkers reveal evidence of radiation exposure
6. VCU Massey Cancer Center sees potential in novel leukemia treatment
7. Study supports urate protection against Parkinsons disease, hints at novel mechanism
8. Novel Natural Sciences Repository Opens Web Portal
9. Novel Anti-Inflammatories May Offer a New Approach for the Treatment of Stroke
10. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
11. Novel radiation therapy safely treats prostate cancer and lowers the risk of recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Peruvian Ayahuasca retreat, ... be awarded annually to and divided between two full-time university students enrolled in ... Amazonian plant medicine. To apply for the scholarship, students are asked to submit ...
(Date:7/24/2017)... ... 24, 2017 , ... The Topricin Companies, formerly Topical Biomedics, ... revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. , ... skin conditions, including cancer. In the short term, overexposure to sun, wind ...
(Date:7/24/2017)... Switzerland (PRWEB) , ... July 24, 2017 , ... Anyone ... to weigh a watermelon, nor would a pharmacist using that same scale to dispense ... risk someone’s health. , These illustrations show why it is important to have ...
(Date:7/24/2017)... ... 2017 , ... Paul Vitenas, MD, FACS is excited to report that he ... attend Allergan’s recent meeting with their Plastics Advisory Board. As one of the top ... bringing a newly defined structure to the aesthetics market. Dr. Vitenas , along ...
(Date:7/24/2017)... ... ... Summer storms are inevitable as weather temperatures in Philadelphia climb. These ... tree damage requiring emergency tree service. Giroud Tree and Lawn provides ... hazardous tree removal. , “A summer storm is like a bully on ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused on the development of ... approval from the Israel Securities Authority to dual-list its common ... stock will commence trading on the TASE on July 12, ... capitalization of the Company, it is expected that Oramed will ...
(Date:7/5/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade cell and tissue hypothermic storage ... announced that it has reached an agreement with WAVI ... to modify its existing credit facility effective June 30, ... agreed to exchange its existing $4.25 million credit facility, ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology: